NUE Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Loading...
Based on the data provided, Nucor Corp (NUE) is not a compelling buy at this moment for a beginner investor with a long-term strategy. The stock is currently in a pre-market decline (-3.11%), and recent analyst downgrades suggest a 'neutral' outlook due to valuation concerns. While the company's financials are strong, with significant YoY growth in revenue, net income, and EPS, the lack of clear upward momentum in technical indicators, mixed sentiment in options data, and insider selling outweigh the positive catalysts. For a long-term investor, it may be better to wait for a more favorable entry point or clearer bullish signals.
The technical indicators show mixed signals. The MACD is positive but contracting, RSI is neutral at 53.399, and moving averages are bullish (SMA_5 > SMA_20 > SMA_200). However, the stock is trading below the pivot level (186.834) in pre-market, with key support at 178.596 and resistance at 195.072. This suggests limited short-term upside potential.
Strong financial performance in Q4 2025, with revenue up 8.64% YoY, net income up 32.36% YoY, and EPS up 35.25% YoY.
Hedge funds are significantly increasing their positions in the stock, with a 1257.47% increase in buying over the last quarter.
Insider selling has increased by 303.08% over the last month, signaling potential concerns from company insiders.
Analyst downgrades from UBS and Morgan Stanley, citing full valuation and muted demand outlook.
Pre-market price decline of -3.11%, indicating weak sentiment.
Nucor Corp reported strong financials for Q4 2025, with revenue of $7.687 billion (up 8.64% YoY), net income of $378 million (up 32.36% YoY), and EPS of $1.65 (up 35.25% YoY). Gross margin also improved to 11.21%, up 26.52% YoY.
Analyst sentiment is mixed to neutral. UBS downgraded the stock to Neutral from Buy with a price target of $183, citing full valuation. Morgan Stanley also downgraded the stock to Equal Weight, while Jefferies and JPMorgan maintain a Buy rating with price targets of $190 and $200, respectively. The consensus view suggests limited upside potential in the near term.
